Brenda Tromp

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema et al. · New England Journal of Medicine · 2021 · 668 citations · Full text

Life Sciences, Hematology, Pharmacology +15

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Thierry Façon, Shaji Kumar, Torben Plesner et al. · The Lancet Oncology · 2021 · 363 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong et al. · Cancer Chemotherapy and Pharmacology · 2013 · 262 citations

Pharmacy, Oncology, Pharmacology +17

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Eric Angevin, Josep Tabernero, Elena Élez et al. · Clinical Cancer Research · 2014 · 206 citations

Pharmacy, Oncology, Pharmacology +17

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

Frits van Rhee, Corey Casper, Peter M. Voorhees et al. · Oncotarget · 2015 · 64 citations · Full text

Life Sciences, Immunology, Oncology +9